<DOC>
	<DOCNO>NCT02486055</DOCNO>
	<brief_summary>This open-label , Phase I study bioavailability safety BPM31510 healthy subject dose 2 3 time daily 4 day , initial cohort 6 subject receive single dose ( pre-study cohort ) . The pre-study cohort subject receive 1600 mg single administration . Cohort 1 Cohort 2 consist 10 patient . The cohort may enrol sequentially .</brief_summary>
	<brief_title>A Safety Study Orally Administered BPM31510 Healthy Subjects</brief_title>
	<detailed_description>This open-label , Phase I study bioavailability safety Berg Pharma Molecule 31510 ( BPM31510 ) healthy subject dose 2 3 time daily 4 day , initial cohort 6 subject receive single dose ( pre-study cohort ) . The pre-study cohort subject receive 1600 mg single administration . Cohort 1 Cohort 2 consist 10 patient . Men woman age 18 , good general health , undergo Screening baseline evaluation 21 day prior dose . The cohort may enrol sequentially . Subjects admit clinic Day 0 . All subject self-administer Day 1 dos study drug supervision clinic staff . In pre-study cohort , subject administer single dose 1600 mg . In Cohort 1 , dos administer two time per day morning even meal le 8 10 hour dos . Immediately administration , subject ingest 6 ounce tap bottle water . Solid food drink , water restrict 2 hour 1 hour dosing . In Cohort 2 dos administer three time per day meal , less 4 6 hour dos . Immediately administration , subject ingest 6 ounce tap bottle water . Solid food drink , water restrict 2 hour 1 hour dosing . Dosing continue additional 4 day outpatient basis last study dose administered clinic Day 5 ( morning dose give Day 5 ) . For pre-study cohort , subject administer single dose 1600 mg breakfast . PK PD sample perform 30 minute prior dose , 0.5 , 1 , 2 4 hour later . Subjects evaluate untoward sign symptom discharge . For cohort 1 2 , Days 1 , 2 , 5 , pharmacokinetic ( PK ) pharmacodynamics ( PD ) sample perform 30 minute prior first dose , 0.5 , 1 , 2 , 4 hour first dose visit BID TID ( additional PK draw Day 1 0.5 , 1 , 2 , 4 second dose TID subject ) . Urine PK/PD collect pre-dose Day 1 , Day 2 , Day 5 . At visit ( Days 1 , 2 , final dose Day5 ) , sample collect chemistry , CBC , INR , PT , PTT , cholesterol , LDL , HDL , vitamin K level . Blood sample PK/PD collect 30 minute prior last dose ( AM ) Day 5 also 0.5 , 1 , 2 , 4 hour dose . Lab sample ( chemistry , etc . ) , also drawn time first PK/PD draw Day 5 . A phone interview conduct few 25 day 35 day last dose Day 5 collect information concomitant medication adverse event ( AEs ) .</detailed_description>
	<mesh_term>Coenzyme Q10</mesh_term>
	<criteria>1 . Men woman , age &gt; 18 year Body mass index ( BMI ) ≥19 ≤30 Good health condition without significant illness , judgment legally qualify professional , accord follow evaluation : medical history , physical examination , vital sign , electrocardiogram ( ECG ) , screen baseline hematology clinical chemistry measure . Subjects child bear potential must agree use one accept method contraception ( list ) trial ( include screen period prior receive trial medication ) , least return menstruation stop trial medication . condom ( male female ) spermicide , diaphragm cervical cap spermicide Intrauterine device ( IUD ) hormonal contraception condom ( male female ) The following subject require use contraception : Subjects practice total abstinence sexual intercourse prefer lifestyle ( periodic abstinence acceptable ) Female subject partner male subject vasectomize least 3 month screen . Postmenopausal females experienced menstruation least 2 year base medical history Female subject surgically sterile ( ie , bilateral oophorectomy , hysterectomy bilateral tubal ligation ) least 3 month screen ) base medical history . Female subject must negative pregnancy test result screen Day1 PT/PTT/INR within normal limit Vitamin K level within normal limit Capable understand comply protocol signing informed consent . Pregnant lactate female subject . Known hypersensitivity study drug ( Coenzyme Q10 ) compound chemically relate . History presence hepatic gastrointestinal illness , condition interferes drug 's absorption , distribution , excretion metabolism . History hepatic , renal , pulmonary , gastrointestinal , epileptic , hematologic psychiatric illness . Hypotension hypertension etiologic need pharmacologic treatment . History exist coagulopathy . History myocardial infarction , angina , and/or heart insufficiency . Nonrecommended electrocardiographic finding , accord investigator criterion . Results laboratory exam normal range unless consider clinically irrelevant investigator . Subject smoker . Subject ingest 5 cup coffee tea day . History alcohol drug abuse . History serious adverse reaction hypersensitivity drug . Ongoing regular use oral prescription drug , exception oral contraceptive . Hospitalization reason within 8 week prior study dose . Participation experimental study ingest experimental drug within 30 day precede study . Donation loss 450 mL blood within 3 month prior Screening/Baseline . Subject consume alcohol 48 hour prior baseline measurement study . Subject report history human immunodeficiency virus . Currently use coenzyme Q10 overthecounter product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Study safety BPM31510 healthy subject</keyword>
</DOC>